TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Atorvastatin Therapy for the Prevention of Atrial Fibrillation (SToP-AF)
Brief Summary: The purpose of this study is to test whether the drug, atorvastatin, will be able to reduce the rate of return of the abnormal beats after using cardioversion. Atorvastatin is a drug approved by the Food and Drug Administration (FDA) for the treatment of high cholesterol but is not approved for preventing abnormal heartbeats. In addition to lowering cholesterol, the drug reduces inflammation. Inflammation seems to help cause atrial fibrillation, a certain type of abnormal heartbeat. In animals, atorvastatin reduces the risk of this type of abnormal beats, and preliminary data in humans supports an effect of atorvastatin and other similar drugs that have the same action on reducing the risk of this type of abnormal beats. We, the researchers at Emory University, would like to learn if this drug could prevent the return of these abnormal heartbeats.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: PROCEDURE; Name: Blood samples; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): N/A
C: Arm Label: Atorvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Atorvastatin (Lipitor); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Atorvastatin Therapy for the Prevention of Atrial Fibrillation (SToP-AF)
Brief Summary: The purpose of this study is to test whether the drug, atorvastatin, will be able to reduce the rate of return of the abnormal beats after using cardioversion. Atorvastatin is a drug approved by the Food and Drug Administration (FDA) for the treatment of high cholesterol but is not approved for preventing abnormal heartbeats. In addition to lowering cholesterol, the drug reduces inflammation. Inflammation seems to help cause atrial fibrillation, a certain type of abnormal heartbeat. In animals, atorvastatin reduces the risk of this type of abnormal beats, and preliminary data in humans supports an effect of atorvastatin and other similar drugs that have the same action on reducing the risk of this type of abnormal beats. We, the researchers at Emory University, would like to learn if this drug could prevent the return of these abnormal heartbeats.


Options:
A: Arm Label: Atorvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: Lipitor | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lipitor; Assigned to Arm(s): Atorvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo atorvastatin | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo atorvastatin; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CANDIS -Targeted Treatment for Cannabis Disorders
Brief Summary: The purpose of this study is to develop a modular treatment program for cannabis use disorders and the evaluation of the effectiveness in a controlled clinical study.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Brief intervention using motivational interviewing | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Brief intervention using motivational interviewing; Assigned to Arm(s): 1
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive-behavioral treatment | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive-behavioral treatment; Assigned to Arm(s): 1
C: Intervention Type: BEHAVIORAL; Name: Psychotherapy; Assigned to Arm(s): N/A
D: Arm Label: Cannabis users; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Cannabis no-users; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Cannabis no-users, Cannabis users

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy And Safety Of Flexible Dose Ranges Of Risperidone Versus Placebo Or Haloperidol In The Treatment Of Manic Episodes Associated With Bipolar I Disorder.
Brief Summary: The purpose of the study is to assess the effectiveness and safety of risperidone (an antipsychotic medication) compared with placebo after 3 weeks of treatment in patients with bipolar disorder who are experiencing manic episodes. A secondary purpose of the study is to assess the maintenance of risperidone effectiveness versus haloperidol (an antipsychotic medication) after 12 weeks of treatment.


Options:
A: Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: risperidone; quetiapine; Assigned to Arm(s): N/A
C: Arm Label: Olanzapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Quetiapine, Drug: Ziprasidone | Arm Label: Quetiapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Risperidone, Drug: Ziprasidone | Arm Label: Risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Ziprasidone | Arm Label: Ziprasidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Ziprasidone | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Olanzapine, Quetiapine, Risperidone, Ziprasidone | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Olanzapine | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Quetiapine | Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): Olanzapine, Quetiapine, Risperidone, Ziprasidone
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: quetiapine, risperidone | Intervention Type: DRUG; Name: quetiapine, risperidone; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Palliative Care for Patients With Cancer
Brief Summary: RATIONALE: Palliative care may help patients with advanced cancer live more comfortably.

PURPOSE: This randomized clinical trial is studying an early intervention palliative care program to see how well it works compared to a standard care program in improving end-of-life care in patients with advanced lung , gastrointestinal, genitourinary, or breast cancer.


Options:
A: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Mini-AFTERc | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mini-AFTERc; Assigned to Arm(s): Intervention group
B: Intervention Type: BEHAVIORAL; Name: Community Interlink Program; Assigned to Arm(s): N/A
C: Arm Label: ENABLE (concurrent palliative care); Type: EXPERIMENTAL; Interventions: Other: counseling intervention, Other: educational intervention, Procedure: psychosocial assessment and care, Procedure: quality-of-life assessment | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: counseling intervention, Procedure: psychosocial assessment and care, Procedure: quality-of-life assessment | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): ENABLE (concurrent palliative care), Usual Care | Intervention Type: OTHER; Name: educational intervention; Assigned to Arm(s): ENABLE (concurrent palliative care) | Intervention Type: PROCEDURE; Name: psychosocial assessment and care; Assigned to Arm(s): ENABLE (concurrent palliative care), Usual Care | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): ENABLE (concurrent palliative care), Usual Care
D: Arm Label: intervention group; Type: ACTIVE_COMPARATOR; Interventions: Device: distress thermometer | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: distress thermometer; Assigned to Arm(s): intervention group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Palliative Care for Patients With Cancer
Brief Summary: RATIONALE: Palliative care may help patients with advanced cancer live more comfortably.

PURPOSE: This randomized clinical trial is studying an early intervention palliative care program to see how well it works compared to a standard care program in improving end-of-life care in patients with advanced lung , gastrointestinal, genitourinary, or breast cancer.


Options:
A: Arm Label: Standard Palliative Care Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Palliative Care Group | Arm Label: Integrated Palliative Care Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Integrated Palliative Care Intervention | Intervention Type: OTHER; Name: Standard Palliative Care Group; Assigned to Arm(s): Standard Palliative Care Group | Intervention Type: OTHER; Name: Integrated Palliative Care Intervention; Assigned to Arm(s): Integrated Palliative Care Group
B: Arm Label: early palliative care; Type: EXPERIMENTAL; Interventions: Behavioral: Interventional palliative care | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard oncologic care | Intervention Type: BEHAVIORAL; Name: Interventional palliative care; Assigned to Arm(s): early palliative care | Intervention Type: BEHAVIORAL; Name: Standard oncologic care; Assigned to Arm(s): Standard care
C: Arm Label: Standard oncologic care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Early Palliative Care; Type: EXPERIMENTAL; Interventions: Other: Early Palliative Care | Arm Label: Psychosocial plus early Palliative Care; Type: EXPERIMENTAL; Interventions: Behavioral: Brief Psychosocial Intervention, Other: Early Palliative Care | Intervention Type: BEHAVIORAL; Name: Brief Psychosocial Intervention; Assigned to Arm(s): Psychosocial plus early Palliative Care | Intervention Type: OTHER; Name: Early Palliative Care; Assigned to Arm(s): Early Palliative Care, Psychosocial plus early Palliative Care
D: Arm Label: ENABLE (concurrent palliative care); Type: EXPERIMENTAL; Interventions: Other: counseling intervention, Other: educational intervention, Procedure: psychosocial assessment and care, Procedure: quality-of-life assessment | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: counseling intervention, Procedure: psychosocial assessment and care, Procedure: quality-of-life assessment | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): ENABLE (concurrent palliative care), Usual Care | Intervention Type: OTHER; Name: educational intervention; Assigned to Arm(s): ENABLE (concurrent palliative care) | Intervention Type: PROCEDURE; Name: psychosocial assessment and care; Assigned to Arm(s): ENABLE (concurrent palliative care), Usual Care | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): ENABLE (concurrent palliative care), Usual Care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Partially-Blind Phase III Randomized Trial of Fulvestrant (Faslodex™) With or Without Concomitant Anastrozole (Arimidex™) Compared With Exemestane in Postmenopausal Women With ER+ve Locally Advanced/Metastatic Breast Cancer Following Progression on Non-Steroidal Aromatase Inhibitors
Brief Summary: RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant, anastrozole, or exemestane may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount of estrogen the body makes. It is not yet known whether giving fulvestrant together with anastrozole is more effective than giving fulvestrant together with a placebo or exemestane alone in treating breast cancer.

PURPOSE: This randomized phase III trial is studying fulvestrant and anastrozole to see how well they work compared to fulvestrant and a placebo or exemestane alone in treating postmenopausal women with locally advanced or metastatic breast cancer.


Options:
A: Arm Label: Arm I; Type: ACTIVE_COMPARATOR; Interventions: Drug: anastrozole | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: anastrozole, Drug: fulvestrant | Intervention Type: DRUG; Name: anastrozole; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: fulvestrant; Assigned to Arm(s): Arm II
B: Intervention Type: DRUG; Name: anastrozole; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: exemestane; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fulvestrant; Assigned to Arm(s): N/A
C: Arm Label: Arm I (anastrozole, gefitinib); Type: EXPERIMENTAL; Interventions: Drug: anastrozole, Drug: gefitinib, Other: laboratory biomarker analysis | Arm Label: Arm II (fulvestrant, gefitinib); Type: EXPERIMENTAL; Interventions: Drug: gefitinib, Drug: fulvestrant, Other: laboratory biomarker analysis | Intervention Type: DRUG; Name: anastrozole; Assigned to Arm(s): Arm I (anastrozole, gefitinib) | Intervention Type: DRUG; Name: gefitinib; Assigned to Arm(s): Arm I (anastrozole, gefitinib), Arm II (fulvestrant, gefitinib) | Intervention Type: DRUG; Name: fulvestrant; Assigned to Arm(s): Arm II (fulvestrant, gefitinib) | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): Arm I (anastrozole, gefitinib), Arm II (fulvestrant, gefitinib)
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anastrozole | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Fulvestrant, Drug: Anastrozole | Intervention Type: DRUG; Name: Fulvestrant; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Anastrozole; Assigned to Arm(s): 1, 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Catechins and Omega-3 Fatty Acids Impact on Fatty Acid Synthase Activity in the Prostate: A Randomized Controlled Trial
Brief Summary: RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of fish oil and/or green tea may prevent prostate cancer.

PURPOSE: This randomized clinical trial is studying how well a fish oil and/or green tea supplement works in preventing prostate cancer in patients with prostatic intraepithelial neoplasia or who are at risk for developing prostate cancer.


Options:
A: Arm Label: Green tea extract; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Green tea extract of Camellia Sinensis | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Green tea extract of Camellia Sinensis followed by placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Green tea extract of Camellia Sinensis; Assigned to Arm(s): Green tea extract | Intervention Type: DIETARY_SUPPLEMENT; Name: Green tea extract of Camellia Sinensis followed by placebo; Assigned to Arm(s): Placebo
B: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Dietary Supplement: defined green tea catechin extract, Other: laboratory biomarker analysis | Arm Label: Arm II; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Other: laboratory biomarker analysis | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Arm II | Intervention Type: DIETARY_SUPPLEMENT; Name: defined green tea catechin extract; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): Arm I, Arm II
C: Arm Label: Arm I (FO, GT catechin extract); Type: EXPERIMENTAL; Interventions: Dietary Supplement: green tea catechin extract, Dietary Supplement: fish oil | Arm Label: ArmII (FO placebo, GT catechin extract); Type: EXPERIMENTAL; Interventions: Dietary Supplement: green tea catechin extract, Other: placebo | Arm Label: Arm III (FO, GT placebo); Type: EXPERIMENTAL; Interventions: Dietary Supplement: fish oil, Other: placebo | Arm Label: Arm IV (FO placebo, GT placebo); Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: green tea catechin extract; Assigned to Arm(s): Arm I (FO, GT catechin extract), ArmII (FO placebo, GT catechin extract) | Intervention Type: DIETARY_SUPPLEMENT; Name: fish oil; Assigned to Arm(s): Arm I (FO, GT catechin extract), Arm III (FO, GT placebo) | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm III (FO, GT placebo), Arm IV (FO placebo, GT placebo) | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm IV (FO placebo, GT placebo), ArmII (FO placebo, GT catechin extract)
D: Arm Label: Polyphenon E Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Polyphenon E | Arm Label: Placebo Administration; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Polyphenon E; Assigned to Arm(s): Polyphenon E Treatment | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Administration

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Study of Osmotic-Release Methylphenidate in Initiating and Maintaining Abstinence in Smokers With ADHD
Brief Summary: The objective of this study is to evaluate whether Osmotic-Release Methylphenidate (OROS MPH), relative to placebo, increases the effectiveness of standard smoking treatment (i.e., nicotine patch and individual smoking cessation counseling) in obtaining prolonged abstinence for smokers with Attention Deficit Hyperactivity Disorder (ADHD).


Options:
A: Arm Label: Osmotic-Release Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Osmotic-Release Methylphenidate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Osmotic-Release Methylphenidate; Assigned to Arm(s): Osmotic-Release Methylphenidate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: open label PR OROS methylphenidate | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: double blind PR OROS methylphenidate | Arm Label: 003; Type: PLACEBO_COMPARATOR; Interventions: Drug: double blind placebo | Intervention Type: DRUG; Name: double blind placebo; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: double blind PR OROS methylphenidate; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: open label PR OROS methylphenidate; Assigned to Arm(s): 001
C: Intervention Type: DRUG; Name: methylphenidate hydrochloride; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: methylphenidate hydrochloride extended-release tablets; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of 4 Diets Varying in Glycemic Index, Glycemic Load, Carbohydrate and Protein, on Weight, Body Composition and Cardio-Vascular Risk Factors
Brief Summary: To investigate the hypothesis that reducing the glycemic load of the diet will improve changes in body composition and cardio-vascular risk factors. The study compares a conventional reduced-fat, high carbohydrate diet with 3 means of reducing glycemic load: changing the carbohydrates to low-GI choices, replacing some of the carbohydrate with protein, or combining both effects to produce the lowest glycemic load.


Options:
A: Intervention Type: BEHAVIORAL; Name: high protein & low glycemic index diets; Assigned to Arm(s): N/A
B: Intervention Type: OTHER; Name: LC-P-LGI diet; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: LC-CONV; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: OTHER; Interventions: Other: Low Glycemic Load Diet, Other: High Glycemic Load Diet | Arm Label: 2; Type: OTHER; Interventions: Other: Low Glycemic Load Diet, Other: High Glycemic Load Diet | Intervention Type: OTHER; Name: Low Glycemic Load Diet; Assigned to Arm(s): 1, 2 | Intervention Type: OTHER; Name: High Glycemic Load Diet; Assigned to Arm(s): 1, 2
D: Arm Label: A: Study diet; Type: PLACEBO_COMPARATOR; Interventions: Drug: metformin and rosiglitazone | Arm Label: B: Study diet plus Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin and rosiglitazone | Arm Label: C: Study diet plus metformin and avandia; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin and rosiglitazone | Intervention Type: DRUG; Name: metformin and rosiglitazone; Assigned to Arm(s): A: Study diet, B: Study diet plus Metformin, C: Study diet plus metformin and avandia

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of 4 Diets Varying in Glycemic Index, Glycemic Load, Carbohydrate and Protein, on Weight, Body Composition and Cardio-Vascular Risk Factors
Brief Summary: To investigate the hypothesis that reducing the glycemic load of the diet will improve changes in body composition and cardio-vascular risk factors. The study compares a conventional reduced-fat, high carbohydrate diet with 3 means of reducing glycemic load: changing the carbohydrates to low-GI choices, replacing some of the carbohydrate with protein, or combining both effects to produce the lowest glycemic load.


Options:
A: Intervention Type: BEHAVIORAL; Name: high protein & low glycemic index diets; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Intervention Type: BEHAVIORAL; Name: High or low Glycemic Index and high or low Protein Diet; Assigned to Arm(s): 1, 2, 3, 4, 5
C: Arm Label: low glycemic index, diabetic diet; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: low glycemic diet instruction | Arm Label: high cereal fibre, diabetic diet; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: high cereal fibre diet instruction | Intervention Type: DIETARY_SUPPLEMENT; Name: low glycemic diet instruction; Assigned to Arm(s): low glycemic index, diabetic diet | Intervention Type: DIETARY_SUPPLEMENT; Name: high cereal fibre diet instruction; Assigned to Arm(s): high cereal fibre, diabetic diet
D: Arm Label: Low Glycemic Index Diet; Type: EXPERIMENTAL; Interventions: Other: Low Glycemic Index diet | Arm Label: High Fiber Diet; Type: ACTIVE_COMPARATOR; Interventions: Other: High Cereal Fibre Diets | Intervention Type: OTHER; Name: Low Glycemic Index diet; Assigned to Arm(s): Low Glycemic Index Diet | Intervention Type: OTHER; Name: High Cereal Fibre Diets; Assigned to Arm(s): High Fiber Diet

Answer: A